Personalized Cancer Vaccine Clinical Trial to Expand Following Promising Early Results

Personalized Cancer Vaccine Clinical Trial to Expand Following Promising Early Results
Blair Willis
A study led by University of Arizona Health Sciences researcher Dr. Julie Bauman will be expanded to further investigate the safety and effectiveness of a personalized cancer vaccine, which has a reported 50% response rate for patients with head and neck cancer in preliminary data.
Today
University of Arizona Cancer CenterJulie-Bauman_klh9390-web.jpg
Dr. Julie E. Baumanis deputy director of the University of Arizona Cancer Center and a professor of medicine and chief of the Division of Hematology and Oncology at the UArizona College of Medicine – Tucson. A study she is leading on the safety and effectiveness of a personalized cancer vaccine has reported a 50% response rate for patients with head and neck cancer.
Kris Hanning/University of Arizona Health SciencesHealthCollege of Medicine - Tucson
Media contact(s)Blair Willis
UArizona Cancer [e-mail]520-626-0331A clinical trial at the  University of Arizona Health Sciences designed to study the safety and effectiveness of a personalized cancer vaccine in combination with the immunotherapy drug Pembrolizumab will expand its cohort after promising preliminary data was presented at the annual meeting of the Society for the Immunotherapy of Cancer.Dr.Julie E. Bauman, deputy director of the  University of Arizona Cancer Center and a professor of medicine and chief of the Division of Hematology and Oncolo...

Source: The University of Arizona: Health - November 9, 2020 Category: Universities & Medical Training Authors: mittank Source Type: research